The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback